Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19209704 | 1.00 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL21952754 | 0.94 | KMT2A (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL21952847 | 0.94 | KMT2A (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23843980 | 0.88 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL29895514 | 0.88 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23843996 | 0.88 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL29895510 | 0.88 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19726539 | 0.88 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL29831011 | 0.85 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19209721 | 0.85 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639349-B2 | Stereoselective synthesis of intermediate for preparation of heterocyclic compound | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2023-05-02 | — | — | US | disclosed |
| US-20210371407-A1 | STEREOSELECTIVE SYNTHESIS OF INTERMEDIATE FOR PREPARATION OF HETEROCYCLIC COMPOUND | TAI GEN BIOTECHNOLOGY CO., LTD (TW) | 2021-12-02 | — | — | US | disclosed |
| US-10596171-B2 | Cap-dependent endonuclease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2020-03-24 | — | — | US | disclosed |
| US-20190224198-A1 | CAP-DEPENDENT ENDONUCLEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224198-A1 | CAP-DEPENDENT ENDONUCLEASE INHIBITORS | RNGTT, RNASEH1, RNASEL | CA1 443/4885CA2 1161/4885CA7 33/4885 |
| US-10596171-B2 | Cap-dependent endonuclease inhibitors | RNGTT, RNASEH1, RNASEL | CA1 443/4885CA2 1161/4885CA7 33/4885 |
| US-20210371407-A1 | STEREOSELECTIVE SYNTHESIS OF INTERMEDIATE FOR PREPARATION OF HETEROCYCLIC COMPOUND | RNGTT, UNG, NUDT21 | CA1 1408/4885CA2 3047/4885CA7 1688/4885 |
| US-11639349-B2 | Stereoselective synthesis of intermediate for preparation of heterocyclic compound | RNGTT, UNG, NUDT21 | CA1 1408/4885CA2 3047/4885CA7 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.